Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia

Blood

Volumn 87, Issue 6, 1996, Pages 2464-2469

  List, Alan F ^a   Spier, Catherine S ^b   Grogan, Thomas M ^b   Johnson, Cynthia ^b   Roe, Denise J ^b   Greer, John P ^b   Wolff, Steven N ^b   Broxterman, Henricus J ^b   Scheffer, George L ^b   Scheper, Rik J ^b   Dalton, William S ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REMISSION; TREATMENT OUTCOME;

EID: 13344278004     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.6.2464.bloodjournal8762464     Document Type: Article

References (47)

1. List AF: Multidrug resistance: Clinical relevance in acute leukemia. Oncology 7:23, 1993
2. + patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 11:262a, 1992 (abstr)
3. List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R, Sandberg AA: Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 78:28, 1991
4. Campos L, Guyotat D, Archibald E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473, 1992
5. + acute myeloid leukemia cells. Blood 82:3157, 1993
6. Herweijor H, Sonneveld P, Baas F, Nooter K: Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 82:1133, 1990
7. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D: Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with stimulation of drug accumulation that can be restored by cyclosporin-A Int J Cancer 45:263, 1990
8. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Haveloc L, Ludwig H, Lechner K: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708, 1991
9. Marie J-P, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586, 1991
10. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730, 1992
11. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652, 1993
12. Ball ED, Lawrence D, Malnar M, et al: Correlation of CD34 and multi-drug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 76:252a, 1990 (abstr, suppl 1)
13. Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H: Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells; Sequential analysis of 15 cases at initial presentation and relapsed stage. Cancer 63:1534, 1989
14. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Scheffer CA: Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin-A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82:1288, 1993
15. Marutama Y, Murohashi I, Nara N, Aoki N: Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukemic blast progenitors in acute myelogenous leukemia. Br J Haematol 72:357, 1989
16. Marie J-P, Faussat-Suberville A-M, Zhou D, Zittoun R: Daunorubicin uptake by leukemic cells: Correlations with treatment outcome and mdr1 expression. Leukemia 7:825, 1993
17. Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo A: Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073, 1990
18. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
19. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475, 1993
20. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357, 1994
21. Abbaszadegan MR, Futscher BW, Klimecki WT, List AF, Dalton WS: Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54:4676, 1994
22. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186, 1995
23. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J, Pinedo HM: Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1:35, 1990
24. Futscher BW, Abbaszadegan MR, Domann F, Dalton WS: Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharmacol 47:1601, 1994
25. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak JPA, Lankelma J: Early multidrug resistance defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 64:857, 1991
26. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ: The drug resistance related protein LRP is a major vault protein. Nature Med 1:578, 1995
27. Rowley JD, Potter D: Chromosome banding patterns in acute nonlymphocytic leukemia. Blood 47:705, 1976
28. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Rowley JD, Golomb HM: Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vitro. Leukemia 2:79, 1988
29. Grogan T, Dalton WS, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S: Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Lab Invest 63:815, 1990
30. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
31. Rosner B (ed): Hypothesis testing: Categorical data, in: Fundamentals of Biostatistics (ed 4). Belmont, CA, Dunberry Press, 1994, p 377
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
33. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
34. Vasu SK, Kedersha NL, Rome LH: cDNA cloning and disruption of the major vault protein alpha gene (mVp-α) in Dictyostelium discoideum. J Biol Chem 268:15356, 1993
35. Rome L, Kedersha N, Chugani D: Unlocking vaults: Organalles in search of a function. Trends Cell Biol 1:47, 1991
36. Dietel M, Arps H, Lage H, Niendorf A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 50:6100, 1990
37. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of humancancer cell lines. Int J Cancer (in press)
38. Dalton WS, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48:1882, 1988
39. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63:923, 1991
40. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hemopoietic stem cells. Cell 66:85, 1991
41. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451, 1994
42. Kita K, Miwa H, Nakase K, Kawakami K, Kobayashi T, Shirakawa S, Tanaka I, Ohta C, Tsutani H, Oguma S, Kyo T, Dohy H, Kamada N, Nasu K, Uchino H (The Japan Cooperative Group of Leukemia/Lymphoma): Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 81:2399, 1993
43. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Lechner K, Bettelheim P: Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 8:423, 1990
44. Del Poetyer G, Stasi R, Venditti A, Suppo G, Bruno A, Masi M, Tabilio A, Papa G: Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:288, 1994
45. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernik PH: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 8:968, 1994
46. Samdani A, Glinsmann-Gibson BJ, Grimm MA, Vijapurkar U, Spier CS, Grogan TM, List AF: Cytogenetics and P-glycoprotein are independent predictors of treatment outcome in acute myeloid leukemia (AML). Exp Hematol 22:761a, 1994 (abstr)
47. Izquierdo MA, van der Zee AGJ, Vermorken JB, van der Valk P, Belien JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230, 1995